State expenditure on medicines for diabetes is growing from year to year, rising again in 2022 to a total of 378.5 million euros — 20.5% more than in the previous year —and the drug that represented the biggest increase in charges for the National Health Service (SNS) last year compared to 2021 was semaglutide, which made the news after becoming a sales success because it was being used for loss weight worldwide.
Readers are the strength and life of the newspaper
PÚBLICO’s contribution to the country’s democratic and civic life lies in the strength of the relationship it establishes with its readers.To continue reading this article, subscribe to PÚBLICO. [email protected]